Ipamorelin Research — Selective GH Secretagogue, Preclinical Studies & Safety Profile

Introduction

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) first described by researchers at Novo Nordisk in the late 1990s. Structurally characterized as Aib-His-D-2-Nal-D-Phe-Lys-NH₂, it belongs to a class of compounds that mimic the endogenous hormone ghrelin and stimulate growth hormone (GH) release by engaging the GH secretagogue receptor (GHSR-1a) in the pituitary and hypothalamus. Ipamorelin is available for laboratory research from Peptide.co.

What distinguishes ipamorelin within the broader family of growth hormone-releasing peptides (GHRPs) is its selectivity profile. Unlike earlier peptides in the GHRP class — such as GHRP-6 and GHRP-2 — ipamorelin stimulates GH secretion in preclinical models without producing concurrent elevations in adrenocorticotropin (ACTH), cortisol, prolactin, thyroid-stimulating hormone (TSH), or the gonadotropins FSH and LH. This pharmacological selectivity, documented by Raun and colleagues in 1998, established ipamorelin as what the original research team called “the first selective growth hormone secretagogue.”

Since its initial characterization, ipamorelin has been investigated in a range of preclinical research contexts, spanning GH-axis modulation, gastrointestinal motility, musculoskeletal physiology, and metabolic endocrinology. The compound is commonly studied in combination with the synthetic GHRH analog CJC-1295, and Peptide.co offers both compounds together as the 2X Blend for laboratory procurement convenience. Ipamorelin in the 2X Blend has been tested to 99.6% purity (Lot YPB.238); certificate of analysis documentation is available at coa.peptide.co.

This research profile consolidates the published preclinical literature on ipamorelin, covering its chemical identity, receptor pharmacology, research findings by domain, comparative pharmacology, and laboratory handling considerations. All language in this document refers strictly to in vitro and in vivo preclinical research.

Chemical Profile

The physicochemical identity of ipamorelin is well established in the primary literature and confirmed in public chemical databases. Key parameters are summarized in the table below.

Structural Features

Ipamorelin is a linear pentapeptide incorporating several non-natural amino acid residues that confer metabolic stability and receptor affinity. The N-terminal α-aminoisobutyric acid (Aib) residue resists proteolytic degradation relative to natural amino acids, extending the half-life of the peptide in biological systems examined in preclinical studies. The D-2-naphthylalanine (D-2-Nal) and D-phenylalanine (D-Phe) residues at positions 3 and 4 are characteristic of the GHRP pharmacophore and are critical for GHSR-1a engagement, as established by structure-activity relationship (SAR) studies in the Ankersen series. The C-terminal lysine residue (Lys-NH₂) serves as an amidated cap that further protects against exopeptidase activity.

The molecular weight of 711.9 g/mol places ipamorelin in the mid-range of research peptides, well above the threshold for passive membrane permeation but amenable to receptor-mediated signaling at nanomolar concentrations. In pituitary cell assays, ipamorelin has demonstrated an EC₅₀ of approximately 1.3 nM, indicating high potency at the GHSR.

Ipamorelin is supplied as a lyophilized (freeze-dried) white powder. For laboratory reconstitution guidance, researchers may use the Peptide.co Reconstitution Calculator to determine appropriate solvent volumes for target concentrations.

Mechanism of Action

GHSR-1a Binding and Pituitary Signaling

Ipamorelin acts as a selective agonist at the growth hormone secretagogue receptor type 1a (GHSR-1a), a G-protein-coupled receptor (GPCR) expressed primarily on somatotroph cells of the anterior pituitary and on neurons of the arcuate nucleus of the hypothalamus. GHSR-1a is the canonical receptor for the endogenous peptide hormone ghrelin, and ghrelin mimetics such as ipamorelin engage the same orthosteric binding site, triggering intracellular signaling cascades that culminate in GH vesicle exocytosis from pituitary somatotrophs.

Upon GHSR-1a engagement in in vitro pituitary preparations, ipamorelin activates Gα_q/11-coupled phospholipase C (PLC), generating inositol trisphosphate (IP₃) and diacylglycerol (DAG). IP₃ mobilizes intracellular calcium from the endoplasmic reticulum, and the resulting rise in intracellular Ca²⁺ concentration directly triggers GH-containing secretory granule fusion with the somatotroph plasma membrane. This is mechanistically analogous to the pathway activated by GH-releasing hormone (GHRH) via its own receptor (GHRHR), though GHRH operates through adenylyl cyclase and cAMP rather than PLC.

Relationship to the GHRH Pathway

Ipamorelin and GHRH act through distinct but synergistic mechanisms to stimulate GH release. GHRH acts primarily on somatotrophs via adenylyl cyclase/cAMP/PKA, increasing GH gene transcription as well as acute secretion. GHSs including ipamorelin appear to amplify GH release by both directly stimulating somatotrophs and, at the hypothalamic level, suppressing somatostatin (SRIF) tone, the primary endogenous inhibitor of GH secretion. This dual action accounts for the synergistic GH response observed in preclinical models when GHRH analogs such as CJC-1295 are co-administered with ipamorelin — a combination widely used in research protocols exploring the GH axis.

GH release stimulated by ipamorelin in rat and porcine models recapitulates the physiological pulsatile pattern of endogenous GH secretion — an advantage over continuous-infusion GH, which triggers receptor downregulation. Raun et al. documented an ED₅₀ of ~80 nmol/kg in anesthetized rats and ~2.3 nmol/kg in anesthetized pigs.

Selectivity: Why Ipamorelin Differs from Other GHRPs

A defining feature of ipamorelin’s mechanism is the absence of off-target activation of other pituitary-adrenal and pituitary-gonadal axes, even at doses substantially exceeding the GH-releasing ED₅₀. In rat studies, doses up to 200 times the GH ED₅₀ produced no statistically significant changes in ACTH, cortisol, prolactin, TSH, FSH, or LH. This contrasts sharply with GHRP-6 and GHRP-2, which produce measurable ACTH and cortisol elevations in preclinical models at efficacious doses, likely because those peptides engage additional receptors or receptor subtypes that activate the hypothalamic-pituitary-adrenal axis.

The molecular basis for this selectivity is thought to reside in the specific geometry of ipamorelin’s interaction with the GHSR orthosteric site. The D-2-Nal residue in position 3, which replaces the D-Trp found in GHRP-6, appears critical: small structural changes in GHRPs substantially alter selectivity profiles across receptor subtypes. This selectivity makes ipamorelin a valuable tool compound for preclinical studies requiring GH/IGF-1 axis interrogation without confounding HPA axis activation.

Preclinical Research Findings

Ipamorelin has been investigated across multiple preclinical research domains since its initial characterization. The following sub-sections summarize key findings organized by research area.

4.1 GH Axis Pharmacology

The foundational characterization of ipamorelin’s GH-releasing activity was published by Raun and colleagues in European Journal of Endocrinology (1998). In rat pituitary cell preparations in vitro, ipamorelin demonstrated an EC₅₀ of approximately 1.3 nM for GH release — high potency comparable to established GHRPs. In anesthetized rat models in vivo, intravenous ipamorelin produced an ED₅₀ of approximately 80 nmol/kg for peak GH elevation, and in anesthetized pigs the ED₅₀ was approximately 2.3 nmol/kg. Crucially, in dose-escalation experiments reaching 200-fold above the GH ED₅₀, plasma ACTH and cortisol remained within baseline ranges, establishing ipamorelin’s selective GH-releasing profile.

Building on structure-activity research, Ankersen and colleagues (Journal of Medicinal Chemistry, 1998) developed peptidomimetic derivatives from ipamorelin in pursuit of oral bioavailability. The parent compound retained high potency in rat pituitary cell and in vivo anesthetized-animal assays, validating the Aib-His-D-2-Nal-D-Phe-Lys-NH₂ scaffold as a pharmacophore reference for GHSR agonist research.

The GH-axis response to ipamorelin in a diabetic disease model was characterized by Johansen, Segev, Landau, Phillip, and Flyvbjerg (Experimental Diabesity Research, 2003). In streptozotocin (STZ)-induced diabetic female mice, intravenous ipamorelin produced exaggerated GH responses (150 ± 35 μg/L in diabetic vs. 62 ± 11 μg/L in non-diabetic animals, p<0.05), yet serum IGF-1 remained suppressed in diabetic mice despite GH stimulation — demonstrating hepatic GH receptor resistance in the STZ model. This investigation highlighted ipamorelin’s utility as a GHSR stimulation probe in metabolic disease research contexts.

4.2 Gastrointestinal Motility and Postoperative Ileus Models

Beyond GH-axis pharmacology, ipamorelin has been investigated in rodent models of gastrointestinal dysmotility — work motivated by the recognition that GHSR-1a is expressed throughout the enteric nervous system and that ghrelin and its mimetics accelerate GI transit in preclinical models.

Venkova, Mann, Nelson, and Greenwood-Van Meerveld (Journal of Pharmacology and Experimental Therapeutics, 2009) examined ipamorelin’s effects in a rodent model of postoperative ileus (POI) induced by laparotomy and intestinal manipulation. Repetitive intravenous dosing of ipamorelin (0.1–1 mg/kg) in this rat model produced statistically significant increases in fecal output, food intake, and body weight gain compared to vehicle-treated animals, indicating accelerated GI transit recovery in the POI setting. This study established ipamorelin as a ghrelin mimetic with prokinetic properties in a surgically relevant preclinical model.

A follow-up study by Greenwood-Van Meerveld, Tyler, Mohammadi, and Pietra (Journal of Experimental Pharmacology, 2012) characterized the gastric emptying mechanism. Ipamorelin at 0.014 μmol/kg IV resulted in 52% ± 11% gastric retention vs. controls, and in ex vivo isolated gastric fundus preparations reversed manipulation-induced contractility inhibition via an atropine-sensitive (cholinergic) pathway — implicating enteric GHSR-1a and cholinergic excitatory neurons in ipamorelin’s prokinetic effects.

4.3 Bone Mineral Content and Musculoskeletal Research

The musculoskeletal effects of ipamorelin in preclinical rodent models have been examined in the context of normal bone growth and under glucocorticoid-induced catabolic conditions.

Svensson, Lall, Dickson, Bengtsson, Rømer, Ahnfelt-Rønne, Ohlsson, and Jansson (Journal of Endocrinology, 2000) administered ipamorelin (0.5 mg/kg/day, continuous subcutaneous infusion) to 13-week-old female Sprague-Dawley rats for 12 weeks. Dual-energy X-ray absorptiometry (DXA) in vivo revealed significant increases in total tibial and vertebral bone mineral content (BMC) in ipamorelin-treated animals compared to vehicle controls. Peripheral quantitative CT (pQCT) measurements indicated that the cortical BMC increase was attributable to increased cross-sectional bone area rather than elevated volumetric mineral density, consistent with GH-mediated periosteal bone growth. This study positioned ipamorelin as a tool compound for investigating GH-dependent bone remodeling in adult rodent models.

Andersen, Malmlöf, Johansen, Andreassen, Ørtoft, and Oxlund (Growth Hormone & IGF Research, 2001) addressed glucocorticoid-induced catabolism in 8-month-old female rats treated with methylprednisolone (9 mg/kg/day, 3 months). Ipamorelin co-administration (100 μg/kg three times daily, subcutaneous) significantly counteracted the glucocorticoid-induced reductions in muscle strength and bone formation: maximum calf muscle tetanic tension increased, and periosteal bone formation rate rose four-fold compared to glucocorticoid-only controls. This work positions ipamorelin as a research tool for probing GHS-mediated protection against steroid-induced musculoskeletal catabolism.

4.4 Metabolic and Inflammatory Research

Ipamorelin’s metabolic research applications were further explored through its GH-releasing activity in diabetic mouse models (Johansen et al., 2003, discussed in section 4.1). The finding that GH hypersecretion coexists with hepatic GH receptor resistance in STZ-diabetic mice illuminated aspects of the GH/IGF-1 axis dysregulation relevant to type 1 diabetes models and established ipamorelin as a pharmacological GHSR agonist for probing this axis in metabolic disease contexts.

Within the broader GHS research landscape, Boccanegra and colleagues (Frontiers in Immunology, 2023) investigated structurally related non-peptide GHSs (EP80317 and JMV2894) in mdx mice, a model of Duchenne muscular dystrophy (DMD). While this study did not employ ipamorelin directly, it demonstrated that GHSR-1a-class ligands can modulate pro-inflammatory (IL-6, CD68) and pro-fibrotic (TGF-β1, Col1a1) gene expression, increase diaphragm contractile force, and reduce fibrosis markers in the mdx model — in some cases independently of GHSR-1a expression, suggesting off-receptor anti-fibrotic mechanisms. This body of work highlights the evolving research interest in GHSs as probes for musculoskeletal inflammation and fibrosis in preclinical disease models.

Ipamorelin vs. Other Growth Hormone Secretagogues

The GHS/GHRP family encompasses structurally diverse peptides and non-peptide compounds that share GHSR-1a agonist activity. Ipamorelin occupies a distinct niche within this family, characterized by high GH-releasing potency combined with a narrow receptor selectivity profile. The comparison below draws on published preclinical pharmacology data.

Ipamorelin vs. GHRP-6

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) was one of the first synthetic GHRPs characterized and has been used in preclinical research for decades. While GHRP-6 and ipamorelin share comparable in vitro GH-releasing potency in rat pituitary cell preparations, GHRP-6 produces significant increases in ACTH, cortisol, and serum prolactin in preclinical models at doses used for GH studies, and is a potent orexigen in rodents. These off-target activities complicate experimental interpretation when researchers aim to study isolated GH-axis effects. Ipamorelin was explicitly developed to overcome these limitations, and Raun et al. (1998) confirmed that even at doses hundreds of times the GH ED₅₀, ipamorelin produced no statistically detectable ACTH or cortisol response in rat models.

Ipamorelin vs. GHRP-2

GHRP-2 (D-Ala-D-βNal-Ala-Trp-D-Phe-Lys-NH₂) is somewhat more potent than ipamorelin at the GHSR in in vitro preparations, but it also activates the hypothalamic-pituitary-adrenal axis, raising cortisol and ACTH in in vivo models. For preclinical studies where HPA axis activation would represent a confound — for example, in stress-sensitive animal models or musculoskeletal research — ipamorelin’s clean ACTH/cortisol profile offers a distinct experimental advantage.

Ipamorelin vs. Hexarelin

Hexarelin (His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH₂) is among the most potent GHRPs in preclinical models but is limited in research applications by pronounced tachyphylaxis — GH responsiveness diminishes rapidly with repeated dosing — and by significant ACTH and cortisol elevation. Hexarelin also has documented cardiac GHSR-1a activity independent of GH release, making it a valuable but pharmacologically complex research tool. Ipamorelin does not exhibit the same degree of tachyphylaxis in preclinical models examined to date, supporting its utility in multi-dose study designs.

Ipamorelin vs. CJC-1295 (GHRH Analog)

CJC-1295 is a synthetic analog of GHRH that acts through the GHRH receptor — a mechanistically distinct pathway from GHSR-1a. Rather than competing with ipamorelin, CJC-1295 and ipamorelin operate through complementary mechanisms: CJC-1295 stimulates somatotrophs through cAMP/PKA signaling and increases pituitary GH content, while ipamorelin activates the same somatotrophs through PLC/Ca²⁺-dependent exocytosis and concurrently suppresses hypothalamic somatostatin tone. In preclinical co-administration models, this dual-pathway stimulation produces synergistic GH release substantially greater than either compound alone, which is the rationale for the CJC-1295/ipamorelin combination available as the 2X Blend.

Storage & Handling

Proper storage of peptide research compounds is essential for maintaining structural integrity, biological activity, and experimental reproducibility. The following guidelines reflect current consensus recommendations for lyophilized synthetic peptides of the GHS class.

Lyophilized (Unreconstituted) Ipamorelin

• Long-term storage: −20°C (standard laboratory freezer) or −80°C for extended archival storage. Avoid temperature cycling.
• Short-term / working stock: 4°C for brief periods (days to weeks) if usage is imminent. Keep desiccated.
• Light exposure: Protect from UV and ambient light. Store in original amber or opaque vials where possible.
• Moisture: Store in a dry environment with desiccant. Moisture ingress into lyophilized peptide vials accelerates hydrolytic degradation. Allow cold vials to reach room temperature before opening to prevent condensation.
• Container integrity: Keep vials sealed until use. Argon or nitrogen headspace backfilling, if available, reduces oxidative degradation risk during extended storage.

Reconstituted Ipamorelin Solutions

• Solvent: Ipamorelin is typically reconstituted with sterile bacteriostatic water or 0.9% saline for in vivo preclinical studies, or with DMSO/aqueous buffer for in vitro assays, depending on the experimental design. Use the Peptide.co Reconstitution Calculator to calculate volumes for desired concentrations.
• Temperature: Store reconstituted solutions at 2–8°C (refrigerated). Do not freeze reconstituted peptide solutions; freeze-thaw cycles accelerate aggregation and degradation.
• Stability window: Reconstituted solutions should be used within 2–4 weeks of preparation. Discard any solution showing visible particulates, color change, or signs of microbial contamination.
• Freeze-thaw: Avoid repeated freeze-thaw cycles for reconstituted solutions. If extended storage is required, aliquot prior to freezing and thaw each aliquot only once.
• pH sensitivity: Maintain solution pH near neutral (6.5–7.5). Strongly acidic or alkaline conditions accelerate peptide bond hydrolysis.

All ipamorelin handling should be performed in accordance with applicable institutional biosafety and chemical hygiene protocols for synthetic peptide research compounds. Consult the certificate of analysis at coa.peptide.co for lot-specific characterization data.

Safety Profile

Note: All safety information below pertains exclusively to preclinical in vitro and in vivo research models. Ipamorelin is not approved for use in humans. This section should not be interpreted as clinical safety data.

Preclinical Tolerability

Ipamorelin has been evaluated across multiple preclinical species and dose regimens without reports of adverse effects in published studies. In the foundational pharmacology studies by Raun et al. (1998), rats and pigs receiving doses up to 200 times the GH-releasing ED₅₀ intravenously showed no observable adverse responses, and no ACTH, cortisol, prolactin, TSH, FSH, or LH perturbations were detected. This separates ipamorelin from other GHRP-class compounds where dose escalation typically elicits HPA axis activation.

In the postoperative ileus model (Venkova et al., 2009), repetitive intravenous dosing at 0.1–1 mg/kg in surgically stressed rats was well tolerated over the study period, with body weight gain and food intake recovery as positive endpoints — consistent with absence of overt systemic toxicity at those dose levels.

In the 3-month glucocorticoid/ipamorelin rat study (Andersen et al., 2001), subcutaneous ipamorelin at 100 μg/kg three times daily (total ~300 μg/kg/day) over 90 days produced no reported adverse effects in adult female rats, and the compound positively counteracted catabolic effects of the co-administered glucocorticoid.

Absence of Tachyphylaxis at Studied Doses

Unlike hexarelin, which exhibits pronounced GH response attenuation with repeated administration in preclinical models, ipamorelin at the doses studied does not appear to produce equivalent tachyphylaxis. This characteristic supports its use in repeated-dose and longitudinal preclinical study designs.

No Published LD₅₀

No specific lethal dose (LD₅₀) for ipamorelin has been reported in the peer-reviewed preclinical literature. The compound has not been evaluated in formal acute toxicity studies at doses approaching lethality. Standard laboratory safety practices for synthetic peptide handling should be observed.

Hormonal Selectivity

The absence of ACTH/cortisol, prolactin, and gonadotropin effects in rat and porcine models distinguishes ipamorelin’s preclinical safety profile from that of GHRP-6, GHRP-2, and hexarelin. This is considered a meaningful preclinical advantage when designing experiments that require isolated GH-axis stimulation without the confounds of stress-hormone co-activation, as highlighted by Raun et al. (1998) in the original characterization.

Limitations of Available Safety Data

Published preclinical safety characterization of ipamorelin remains limited relative to more extensively studied peptides. Formal toxicokinetic studies, organ toxicity assessments, and reproductive toxicology data have not been published in the accessible peer-reviewed literature. Researchers should exercise appropriate precaution and conduct institutional risk assessments prior to use in preclinical study designs.

Frequently Asked Questions

References

1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–61. doi: 10.1530/eje.0.1390552. PMID: 9849822.
2. Ankersen M, Johansen NL, Madsen K, Hansen BS, Raun K, Nielsen KK, Thogersen H, Hansen TK, Peschke B, Lau J, Lundt BF, Andersen PH. A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. J Med Chem. 1998;41(19):3699–704. doi: 10.1021/jm9801962. PMID: 9733495.
3. Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110–6. doi: 10.1124/jpet.108.149211. PMID: 19289567.
4. Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012;4:149–55. doi: 10.2147/JEP.S35396. PMID: 27186127.
5. Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569–77. doi: 10.1677/joe.0.1650569. PMID: 10828840.
6. Andersen NB, Malmlöf K, Johansen PB, Andreassen TT, Ørtoft G, Oxlund H. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001;11(5):266–72. doi: 10.1054/ghir.2001.0239. PMID: 11735244.
7. Johansen PB, Segev Y, Landau D, Phillip M, Flyvbjerg A. Growth hormone (GH) hypersecretion and GH receptor resistance in streptozotocin diabetic mice in response to a GH secretagogue. Exp Diabesity Res. 2003;4(2):73–81. doi: 10.1155/EDR.2003.73. PMID: 14630569.
8. Boccanegra B, Cappellari O, Mantuano P, et al. Growth hormone secretagogues modulate inflammation and fibrosis in mdx mouse model of Duchenne muscular dystrophy. Front Immunol. 2023;14:1119888. doi: 10.3389/fimmu.2023.1119888. PMC: PMC10130389.
9. National Center for Biotechnology Information. Ipamorelin [Internet]. PubChem Compound Summary; CID 9831659. Bethesda (MD): National Library of Medicine (US); [cited 2026 Mar 9]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Ipamorelin.